Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
Public ClinicalTrials.gov record NCT07673081. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and all-cause acute respiratory illness (ARI), lower respiratory tract disease (LRTD), and other outcomes of interest, within a target trial emulation (TTE) framework
Study identification
- NCT ID
- NCT07673081
- Recruitment status
- Active, not recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 293,334 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2026
- Primary completion
- Sep 29, 2026
- Completion
- Sep 29, 2026
- Last update posted
- Aug 19, 2026
2026
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer | New York | New York | 10001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Respiratory Syncytial Virus (RSV) trials
Other public records listing Respiratory Syncytial Virus (RSV). Sorted by last update posted; newest first. Not a recommendation.
- NCT07768345: A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults Not yet recruiting
- NCT07249320: Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants Active, not recruiting
- NCT05443607: Transplacental Transmission of RSV (TTRSV) Active, not recruiting
- NCT06564194: A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV Active, not recruiting
- NCT07185399: Systems Biological Analysis of Immune Responses to RSV Vaccine Active, not recruiting
- NCT07050732: Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07673081, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Aug 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07673081 live on ClinicalTrials.gov.